Aurobindo Pharma has received final approval from the US health regulator to market and manufacture Ramipril Capsules, used for treating hypertension, in the American market. The company has received approval from the USFDA for Ramipril Capsules in strengths of 1.25 mg, 2.5 mg, 5 mg and 10 mg. The product has a market size of approximately USD 95 million for the twelve months ending September 2010 according to IMS and will be launched soon. Ramipril Capsules, which are the generic equivalent of King Pharmaceuticals Altace, are indicated for the treatment of hypertension and falls under the cardiovascular therapeutic segment.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1872.60 |
| Dr. Reddys Labs. | 1376.30 |
| Cipla | 1453.50 |
| Zydus Lifesciences | 1121.65 |
| Lupin | 2407.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: